One of the underlying molecular adaptations of the cancer cell is the expression of AR variants that, devoid of their ligand‐binding domain, are transcriptionally active in an androgen and anti‐androgen independent manner and may drive therapy resistance [1]. The gene discussed is AR; the disease is cancer.